Overweight and obesity are health problems of epidemic proportions, increasing the risk not only of cardiovascular disease and type 2 diabetes mellitus but also of various types of cancer. Obesity is strongly associated with changes in the physiological function of adipose tissue, leading to insulin resistance, chronic inflammation, and altered secretion of adipokines. Several of these factors, such as insulin resistance, increased levels of leptin, plasminogen activator inhibitor-1, and endogenous sex steroids, decreased levels of adiponectin, and chronic inflammation, are involved in carcinogenesis and cancer progression. This article reviews these mechanisms, focusing on adipose tissue dysfunction as a unifying causal factor. Although understanding of the link between obesity and cancer might provide therapeutic targets, preventing overweight and obesity still remains number one priority. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2569–78)

Excess body weight is a health problem of epidemic proportions that is not restricted to the developed countries (1-3), but affects people worldwide (3). Overweight and obesity increase the risk of cardiovascular disease and type 2 diabetes mellitus (4-6) and account for a substantial proportion of global morbidity and mortality (3, 4, 7). Moreover, overweight and obesity are now established risk factors for cancer and cancer-related mortality (8-11). It is thought that the metabolic changes associated with obesity, particularly abdominal obesity, and changes in adipocyte function underlie this increased risk. Knowledge of the pathophysiological mechanisms underlying the association between obesity and malignancy may be important for the development of preventive and therapeutic strategies for cancer.

The purpose of this overview is to evaluate the association between obesity and the occurrence of various cancers and to review the pathophysiological mechanisms involved. We propose that adipose tissue dysfunction has a prominent role in cancer pathogenesis and progression.

Overweight (defined as a body mass index [BMI] of 25 to 29.9 kg/m2) and obesity (BMI ≥ 30 kg/m2) are associated with an increased all-cause mortality (4, 7), and cancer accounts for a substantial proportion of obesity-related deaths (7, 10, 12). In 2003, it was estimated that overweight and obesity were responsible for 14% of all cancer deaths in men and 20% of those in women in the United States (12), which is consistent with the poorer outcome of cancer in overweight and obese subjects (10). Excess bodyweight is not only associated with cancer mortality but is also associated with an increased incidence of several types of cancer. Recent meta-analyses (10, 13, 14) have shown that an increased BMI is associated with an increased incidence of endometrial, colorectal, and postmenopausal breast cancer (Table 1). In addition, obesity has recently been shown to be associated with an increased risk of esophageal adenocarcinoma, thyroid cancer, renal cancer, multiple myeloma, gallbladder cancer in women, leukemia, pancreatic cancer, non-Hodgkin lymphoma, and ovarian cancer (10, 11, 15). However, data on the association between obesity and prostate cancer are ambiguous, with a high BMI being associated with a higher risk of high-grade prostate cancer but with a lower risk of low-grade prostate cancer (16).

Table 1.

Body mass index and risk of several cancer types

Type of CancerMenWomenReference
RR (95% CI)*RR (95% CI)*
Endometrial – 2.89 (2.62-3.18) Reeves (2007) (ref. 10) 
– 1.59 (1.50-1.68) Renehan (2008) (ref. 11) 
Esophageal adenocarcinoma 1.52 (1.33-1.74) 1.51 (1.31-1.74) Renehan (2008) (ref. 11) 
Postmenopausal breast – 1.40 (1.31-1.49) Reeves (2007) (ref. 10) 
– 1.12 (1.08-1.16) Renehan (2008) (ref. 11) 
Colon 1.30 (1.25-1.35) 1.12 (1.07-1.18) Larsson (2007) (ref. 12) 
1.53 (1.33-1.75) 1.09 (0.93-1.28) Moghaddam (2007) (ref. 13)§ 
1.24 (1.20-1.28) 1.09 (1.05-1.13) Renehan (2008) (ref. 11) 
Rectal 1.12 (1.09-1.16) 1.03 (0.99-1.08) Larsson (2007) (ref. 12) 
1.27 (1.17-1.37) 1.02 (0.85-1.22) Moghaddam (2007) (ref. 13)§ 
1.09 (1.06-1.12) 1.02 (1.00-1.05) Renehan (2008) (ref. 11) 
Thyroid 1.33 (1.04-1.70) 1.14 (1.06-1.23) Renehan (2008) (ref. 11) 
Renal 1.24 (1.15-1.34) 1.34 (1.25-1.43) Renehan (2008) (ref. 11) 
Pancreatic 1.16 (1.05-1.28) 1.10 (1.02-1.09) Larsson (2007) (ref. 14) 
1.07 (0.93-1.23) 1.12 (1.02-1.22) Renehan (2008) (ref. 11) 
Ovarian – 1.14 (1.03-1.27) Reeves (2007) (ref. 10) 
– 1.03 (0.99-1.08) Renehan (2008) (ref. 11) 
Multiple myeloma 1.11 (1.05-1.18) 1.11 (1.07-1.15) Renehan (2008) (ref. 11) 
Gallbladder 1.09 (0.99-1.21) 1.59 (1.02-2.47) Renehan (2008) (ref. 11) 
Leukemia 1.08 (1.02-1.14) 1.17 (1.04-1.32) Renehan (2008) (ref. 11) 
Non-Hodgkin lymphoma 1.06 (1.03-1.09) 1.07 (1.00-1.14) Renehan (2008) (ref. 11) 
Prostate high-grade 1.25 (1.06-1.49) –  
Prostate low-grade 0.85 (0.77-0.93) – Hsing (2007) (ref. 15) 
Type of CancerMenWomenReference
RR (95% CI)*RR (95% CI)*
Endometrial – 2.89 (2.62-3.18) Reeves (2007) (ref. 10) 
– 1.59 (1.50-1.68) Renehan (2008) (ref. 11) 
Esophageal adenocarcinoma 1.52 (1.33-1.74) 1.51 (1.31-1.74) Renehan (2008) (ref. 11) 
Postmenopausal breast – 1.40 (1.31-1.49) Reeves (2007) (ref. 10) 
– 1.12 (1.08-1.16) Renehan (2008) (ref. 11) 
Colon 1.30 (1.25-1.35) 1.12 (1.07-1.18) Larsson (2007) (ref. 12) 
1.53 (1.33-1.75) 1.09 (0.93-1.28) Moghaddam (2007) (ref. 13)§ 
1.24 (1.20-1.28) 1.09 (1.05-1.13) Renehan (2008) (ref. 11) 
Rectal 1.12 (1.09-1.16) 1.03 (0.99-1.08) Larsson (2007) (ref. 12) 
1.27 (1.17-1.37) 1.02 (0.85-1.22) Moghaddam (2007) (ref. 13)§ 
1.09 (1.06-1.12) 1.02 (1.00-1.05) Renehan (2008) (ref. 11) 
Thyroid 1.33 (1.04-1.70) 1.14 (1.06-1.23) Renehan (2008) (ref. 11) 
Renal 1.24 (1.15-1.34) 1.34 (1.25-1.43) Renehan (2008) (ref. 11) 
Pancreatic 1.16 (1.05-1.28) 1.10 (1.02-1.09) Larsson (2007) (ref. 14) 
1.07 (0.93-1.23) 1.12 (1.02-1.22) Renehan (2008) (ref. 11) 
Ovarian – 1.14 (1.03-1.27) Reeves (2007) (ref. 10) 
– 1.03 (0.99-1.08) Renehan (2008) (ref. 11) 
Multiple myeloma 1.11 (1.05-1.18) 1.11 (1.07-1.15) Renehan (2008) (ref. 11) 
Gallbladder 1.09 (0.99-1.21) 1.59 (1.02-2.47) Renehan (2008) (ref. 11) 
Leukemia 1.08 (1.02-1.14) 1.17 (1.04-1.32) Renehan (2008) (ref. 11) 
Non-Hodgkin lymphoma 1.06 (1.03-1.09) 1.07 (1.00-1.14) Renehan (2008) (ref. 11) 
Prostate high-grade 1.25 (1.06-1.49) –  
Prostate low-grade 0.85 (0.77-0.93) – Hsing (2007) (ref. 15) 

*Relative risk (RR) and 95% confidence interval (CI).

Estimated trends in the RR associated with every 10 kg/m2 increase in Body Mass Index (BMI).

RR associated with every 5 kg/m2 increase in BMI.

§RR with BMI ≥ 30 kg/m2 compared to BMI < 25 kg/m2.

The obesity epidemic is not limited to adults but affects children and adolescents. In 2003-2004, 17.1% of American children and adolescents aged 2 to 19 years were overweight or obese (1). A recent study has shown that excess bodyweight in adolescence carries an increased risk of colon cancer mortality in adulthood in men (relative risk [RR], 2.1; 95% confidence interval [CI], 1.1-4.1) and women (RR, 2.0; 95% CI, 1.2-3.5; ref. 17). These results underline the necessity of preventing childhood obesity.

In addition to its lipid-storing capacity, adipose tissue is a highly active endocrine and metabolic organ. Adipose tissue, which is made up of various cell types, such as adipocytes, pre-adipocytes, fibroblasts, macrophages, and blood vessels, produces numerous adipokines, such as leptin, adiponectin, plasminogen activator inhibitor (PAI)-1, vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-α), and interleukin (IL) -6. As adipose tissue expands, adipocytes enlarge and the adipose tissue starts to produce chemotactic factors, such as monocyte chemoattractant protein (MCP) -1, that attract monocytes/macrophages into adipose tissue (18). The subsequent increased production of adipokines and inflammatory cytokines and the decreased production of adiponectin (19), in combination with the inability of adipose tissue to store the surplus free fatty acids (FFAs; ref. 20), can be considered to reflect adipose tissue dysfunction (Fig. 1). These obesity-associated disturbances of adipose tissue function are believed to play a crucial role in the development of insulin resistance, type 2 diabetes, and obesity-related cardiovascular disease (21-24).

Figure 1.

Dysfunctional adipose tissue in obesity. FFA, free fatty acids; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumor necrosis factor-α.

Figure 1.

Dysfunctional adipose tissue in obesity. FFA, free fatty acids; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumor necrosis factor-α.

Close modal

Despite being extensively studied, the pathogenesis of insulin resistance in obesity is still not completely understood. High levels of FFAs, as seen in obesity, reduce insulin-mediated glucose uptake by the GLUT4 transporter and inhibit the insulin receptor-mediated tyrosine phosphorylation of the insulin receptor substrate (IRS) -1 (25). TNF-α induces insulin resistance in a similar way. By stimulating the serine phosphorylation of IRS-1 and converting IRS-1 into an inhibitor of insulin receptor tyrosine kinase activity, TNF-α attenuates the insulin signaling cascade (26). In turn, the suppression of lipolysis by insulin is inhibited in insulin resistance, resulting in an increased release of FFAs, thereby setting up a vicious cycle of events (25, 26). Under normal conditions, adiponectin increases insulin sensitivity directly, by stimulating tyrosine phosphorylation of the insulin receptor. Adiponectin may also indirectly protect against the development of insulin resistance by activating 5′-AMP-activated protein kinase (AMPK), leading to increased fatty acid oxidation and decreased influx of FFAs into the liver, which contributes to reduced hepatic glucose production and VLDL synthesis (27). Conceivably, the paradoxical decrease in adiponectin levels in obesity (28) may play an important role in the development of insulin resistance.

Obesity is thought to induce a state of chronic low-grade inflammation (29, 30) and is associated with an increased number of macrophages in adipose tissue (31). The exact trigger for the chronic inflammatory response of adipose tissue is not known but may be hypoxia. It is proposed that as adipose tissue enlarges, individual cells are further from blood vessels and become poorly oxygenated (32). This state of relative hypoxia activates hypoxia-inducible factor (HIF) -1α, a key regulator of oxygen homeostasis. The subsequent increased expression of IL-6 and leptin (33), the decreased production of adiponectin (34), and the HIF-1α-mediated attraction of macrophages into adipose tissue (35) may initiate the inflammatory response in adipose tissue. Moreover, the increased production of TNF-α by adipocytes stimulates the production of MCP-1 by preadipocytes and endothelial cells (18), with the result that macrophages are attracted to adipose tissue. Additional chemotactic factors, including leptin (36), may also contribute to the accumulation of macrophages in dysfunctional adipose tissue. It has been shown that the number of macrophages in adipose tissue decreases significantly after obese individuals undergo bariatric surgery and that this decrease is associated with changes in the expression of genes of the stroma vascular fraction of adipose tissue, which are involved in macrophage attraction (35). Adipose tissue macrophages are largely responsible for TNF-α expression and, to a lesser degree, IL-6 expression in adipose tissue (31).

Distribution of adipose tissue is important in the metabolic complications of obesity. Abdominal adipose tissue, which is strategically located to the liver, is especially associated with an abnormal metabolic profile (37). Elevated macrophage infiltration in omental versus subcutaneous adipose tissue and increased concentrations of IL-6 in the portal circulation in obese subjects contribute to systemic inflammation as seen in abdominal obesity (38, 39). Furthermore, serum levels of IL-6, associated with visceral adipose tissue, influence insulin levels (40).

Although BMI is an adequate indicator of overweight and obesity in clinical studies, it does not reflect the obesity-induced metabolic changes that may be involved in carcinogenesis. The presence of metabolic syndrome (defined as a cluster of abdominal obesity, hypertension, hypertriglyceridaemia, low HDL-cholesterol, and hyperglycemia ref. 41), might be a better qualitative indicator of the carcinogenic potential of obesity (42). Various pathophysiological mechanisms linking obesity to cancer have been postulated. We propose that dysfunctional adipose tissue is a unifying causal factor.

The relationship between insulin resistance and adipose tissue dysfunction is complicated, as both can be caused by the other. Insulin resistance and the insulin-like growth factor (IGF) -1 system may explain in part the link between obesity and cancer. In a state of insulin resistance, which is frequently seen in obesity (43), serum insulin levels increase to avert hyperglycemia. Insulin up-regulates growth hormone (GH) receptors in the liver, which stimulates the hepatic production of IGF-1 (44). Thus, serum IGF-1 levels would be expected to be correlated with BMI, but levels of IGF-1 are normal or low in obese subjects (45). This fact might be explained by the inhibitory effect of high levels of insulin on the secretion of IGF-binding protein (IGFBP) -1 and 2. The subsequent increase in the levels of free IGF-1 leads to increased negative feedback on GH secretion, which ultimately leads to lower plasma levels of IGF-1 (46, 47). In obese subjects, free IGF-1 levels do not respond to insulin administration and tend to be higher than in lean subjects (48). Both insulin and IGF-1 are believed to play a role in cancer development through binding to the insulin receptor (IR) and IGF-1 receptor (IGF-1R). IGF-1 can inhibit apoptosis and stimulate cell proliferation through several downstream signaling networks, including the phosphatidylinositol 3-kinase (PI3-K) -AKT system and the Ras/Raf/mitogen-activated-protein-kinase (MAPK) systems, respectively (49). Interestingly, the expression of IGF-1 receptor is increased in some tumors, which suggests that these neoplasms may be stimulated by systemic levels of IGF-1 (50, 51). In addition, IGF-1 mediates cell migration and invasion in human pancreatic carcinoma cells, most likely by inducing the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) (ref. 52). Besides regulating glucose transport, insulin has mitogenic and anti-apoptotic properties mediated through pathways to some extent similar to those of IGF-1 (53, 54). This mitogenic, anti-apoptotic environment caused by increased serum levels of insulin and IGF-1 accelerates the stepwise accumulation of genetic mutations and thereby favors carcinogenesis (49). Clinical studies have shown that patients with high levels of IGF-1 have an increased risk of several types of cancer, including colorectal, prostate, and postmenopausal breast cancer (49). Hyperinsulinaemia is also an independent risk factor for breast cancer in postmenopausal women (55) and increases the risk of colorectal and endometrial cancer; however, these results are ambigious (56, 57). In addition, diabetes mellitus, a disease characterized by insulin resistance, is associated with an increased risk of breast, colorectal, pancreatic, and bladder cancer (58-61). Insulin resistance is likely to play a prominent role in carcinogenesis, and it appears to be of one the major mechanisms involved in the obesity-cancer link.

Adipose tissue produces a variety of hormones and cytokines, known as adipokines. Adipose tissue dysfunction results in altered serum levels of adipokines, which may be directly involved in obesity-related carcinogenesis.

Adiponectin

Adiponectin, an adipokine that is exclusively derived from adipocytes, has significant anti-inflammatory and insulin-sensitizing effects (62, 63). Plasma concentrations of adiponectin are reduced in obesity (28), and clinical studies point toward there being an inverse relation between serum levels of adiponectin and the risk of breast, endometrial, prostate, colorectal, and kidney cancer (64-68). The role of adiponectin in cancer etiology in not yet fully understood. Although it is possible that adiponectin provides indirect protection against carcinogenesis, by affecting insulin sensitivity and the inflammatory state, it has direct anti-carcinogenic effects, many of which are mediated through the AMP-activated protein kinase (AMPK) system via two receptors, AdipoR1 and R2. Activated AMPK plays an important role in the regulation of growth arrest and apoptosis by stimulating p53 and p21 (69). Moreover, phosphorylation of the tumor suppressor, tuberous sclerosis complex (TSC)2, by activated AMPK (70) and the subsequent inhibition of mammalian target of rapamycin may be an important downstream signaling pathway by which adiponectin counteracts carcinogenesis. Independent of AMPK activation, adiponectin decreases the production of reactive oxygen species (ROS; ref. 71), which may result in decreased activation of MAPK (72) and thereby inhibition of cell proliferation. In vitro, adiponectin inhibits the growth of several breast cancer cell lines (73) and induces apoptosis of myelomonocytic (leukemia) lineage cells (74). Adiponectin also has been shown to inhibit tumor angiogenesis in in vitro experiments (75). These effects appear to be partially mediated through the activation of a cascade of apoptosis executor proteins, caspase-8,-9, and -3, leading to apoptosis in vascular endothelial cells.

A number of studies with fatless A-ZIP/F-1 transgenic mice have suggested that insulin resistance and inflammation have a greater role than adipokines (76). A-ZIP/F-1 mice, which are diabetic and display a state of inflammation but do not have detectable levels of adipokines, are more susceptible to carcinogen-induced tumor formation and growth than are wild-type mice (77). The accelerated tumor formation in mice without detectable adipokine levels suggests that adiponectin may protect against carcinogenesis. Thus, the decreased plasma levels of adiponectin in obesity (28) may be associated with the increased risk of cancer in obesity.

Leptin

The 16-kDa protein hormone leptin, which is secreted by adipocytes, plays a pivotal role in regulating the energy balance, by decreasing appetite and increasing metabolism. Levels of leptin are raised in obese subjects, which suggests that obesity is associated with leptin resistance (78). The findings of clinical studies of the relationship between systemic leptin levels and breast or prostate cancer are inconsistent (16, 79, 80), but an association has been reported for colorectal cancer (81-83) and for endometrial cancer (84, 85). Interestingly, many colorectal, breast, and endometrial cancers overexpress the leptin receptor ObR (86-88). Experimental studies have shown that leptin has mitogenic effects in cancer cell lines, depending on the type of cancer: it stimulates the growth of breast, esophagus, and prostate cancer, but inhibits the growth of pancreatic cancer cells (89). Mitogenic and anti-apoptotic effects of leptin have been described in both colon and prostate cancer cell lines. Inhibition of MAPK and PI3-K inhibited these effects, indicating that these pathways underlie the growth-promoting effect of leptin (90, 91). Although leptin appears to favor cancer cell growth locally, more studies are required to assess the clinical significance of elevated levels of this pleiotropic hormone in relation to the link between obesity and cancer.

PAI-1

PAI-1 is a serine protease inhibitor produced by adipocytes, endothelial cells, and stromal cells in visceral adipose tissue (92). PAI-1 is not only produced by adipose tissue, but also affects adipocyte differentiation and insulin signaling (93). Moreover, PAI-1 inhibits uPA, which acts as an inducer of fibrinolysis and extracellular matrix degradation, and is associated with tumor cell invasion and metastasis. Paradoxically, PAI-1 is involved in tumor growth, invasion, metastasis, and angiogenesis by interacting with vitronectin, integrins, and other components of the uPA system and by affecting the extracellular matrix (94-96).

Overexpression of PAI-1 has been found in many obesity-related types of cancer and is associated with the progression of breast, endometrial, colorectal, thyroid, renal, and prostate cancer (97-102). In addition to autocrine production by tumor cells, systemic levels of PAI-1 (e.g., produced by immune cells or adipocytes in obesity) appear to be essential for its tumor-promoting effects, though level dependent (103). Inhibition of PAI-1 might be a potential target in cancer therapy. Indeed, treatment with PAI-1 inhibitor of Min mice, which have a defect in the adenomatous polyposis coli (Apc) gene, suppressed intestinal polyp formation (104). It has been hypothesized recently that, as a consequence of metabolic syndrome, the up-regulation of PAI-1 expression predisposes breast cancer to more aggressive stages (105). This hypothesis supports the role of PAI-1 in promoting cell migration and tumor angiogenesis (106). Although the amount of studies of PAI-1 in obesity-induced carcinogenesis is modest, results so far make PAI-1 a plausible culprit for the increased risk of cancer mortality in obesity.

It is well recognized that inflammation is involved in the promotion and progression of cancer (107, 108). For example, local chronic inflammation is seen in inflammatory bowel disease and Barrett's esophagus, disorders that carry an increased risk of colorectal cancer and esophageal adenocarcinoma, respectively (100-111). In fact, (pre-) malignant lesions could be referred to as inflamed, because the tumor microenvironment contains a variety of leukocytes and inflammatory factors (107). The precise role of these inflammatory components in carcinogenesis is not completely understood and therefore continues to be an appealing avenue of research.

Obesity-induced inflammation, a key feature of adipose tissue dysfunction, is thought to be an important link between obesity and cancer. Obesity reflects a state of low-grade systemic inflammation. Serum levels of CRP, an inflammatory marker, are increased in individuals with a higher BMI (112), and weight loss leads to a decrease in CRP concentration, whereas weight gain leads to an increase in CRP concentrations (113). Raised serum levels of CRP are correlated with an increased risk of cancer (114). Although the causes of inflammation in obesity are not fully understood, the consequences are more evident, with increased systemic levels of proinflammatory cytokines, such as TNF-α and IL-6, which are secreted in large quantities by dysfunctional adipose tissue (29). Several of the proinflammatory factors in obesity are believed to be involved in carcinogenesis (Fig. 2).

Figure 2.

Potential pathways directly linking obesity with cancer. AdipoR1/R2, adiponectin receptor 1/2; AMPK, 5′-AMP-activated protein kinase; IGF-1, insulin-like growth factor-1; IGF-1R, insulin-like growth factor-1 receptor; IKK, IκB kinase; IL-6, interleukin-6; IL-6R, interleukin-6 receptor; IR, insulin receptor; IRS-1, insulin receptor substrate-1; JAK, Janus kinase; MAPK, mitogen-activated-protein-kinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB; ObR, leptin receptor; PAI-1, plasminogen activator inhibitor-1; PI3-K, phosphatidylinositol 3-kinase; ROS, Reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor- α; TNF-R1, tumor necrosis factor-receptor 1; TRADD, TNFRSF1A-associated via death domain; TRAF2, TNF receptor-associated factor 2; TSC2, tuberous sclerosis complex 2; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

Figure 2.

Potential pathways directly linking obesity with cancer. AdipoR1/R2, adiponectin receptor 1/2; AMPK, 5′-AMP-activated protein kinase; IGF-1, insulin-like growth factor-1; IGF-1R, insulin-like growth factor-1 receptor; IKK, IκB kinase; IL-6, interleukin-6; IL-6R, interleukin-6 receptor; IR, insulin receptor; IRS-1, insulin receptor substrate-1; JAK, Janus kinase; MAPK, mitogen-activated-protein-kinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB; ObR, leptin receptor; PAI-1, plasminogen activator inhibitor-1; PI3-K, phosphatidylinositol 3-kinase; ROS, Reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor- α; TNF-R1, tumor necrosis factor-receptor 1; TRADD, TNFRSF1A-associated via death domain; TRAF2, TNF receptor-associated factor 2; TSC2, tuberous sclerosis complex 2; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

Close modal

As a member of the TNF superfamily, TNF-α plays a vital role in adaptive responses of the immune system and other organ systems (115). When TNF was identified as a macrophage-derived factor that could induce necrosis in tumor cells (116), hopes were raised that the cytokine would be a powerful anticancer agent. However, in recent years, the role of TNF-α in malignancy is being reconsidered, and it is now suggested that TNF-α is involved in carcinogenesis and cancer progression (117-119). These contradictory effects of TNF-α can partly be explained by its role in the regulation of apoptosis. When TNF-α binds to its primary receptor, TNF-R1, a downstream signaling cascade leads to activation of nuclear factor (NF) -κB (120). This in turn leads to the up-regulation of several negative regulators of apoptosis, such as c-FLIP and cIAP1, which promote cell survival (121). TNF-α has been reported to have tumor-promoting activity in various experimental cancers (122), and a variety of tumor cells produce TNF-α (108). TNF-α produced by ovarian cancer cells was recently found to stimulate a constitutive network of factors, including VEGF and chemokines CXCR4 and CXCL12, that promote tumor progression (117). Whether increased systemic levels of TNF-α, as seen in obesity (29), act through the same signaling network to promote tumor development and progression is not fully clear; however, increased TNF-α serum levels are correlated with an increased risk of cancer-related death and, to a lesser degree, with overall cancer events (123). Systemic TNF-α might also be involved in the early development of some tumors, as a recent study showed elevated TNF-α levels to be associated with an increased risk of colorectal adenomas (124).

Under physiological conditions, IL-6 has an essential role in the acute inflammatory response and affects the maturation of B cells. Recent findings, however, suggest that this essential cytokine is associated with several disease processes, including chronic inflammatory diseases and cancer (125). Systemic levels of IL-6 are elevated in obesity (29) and, akin to TNF-α, systemic levels of IL-6 are correlated with overall cancer death and increased risk of cancer precursor lesions (123, 124). In addition, levels of the IL-6 promoter genotype have been associated with several hematological cancers (126). Effects of IL-6 on cell proliferation and cell survival are likely to be mediated through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)3 pathway (127).

Obesity-induced inflammation involves other inflammatory components that could contribute to the development of cancer. These components include matrix metalloproteinases (MMPs), which are associated with cancer-cell invasion and metastasis (128). Strongly induced mRNA levels of several MMPs in obesity, as well as their role in adipocyte differentiation, might represent a potential molecular link between obesity and cancer (129, 130). Oxidative stress, as part of chronic inflammation, may also create a microenvironment favorable to tumor development in obesity (131).

The impact of adiposity on the synthesis and bioavailability of endogenous sex steroids is of substantial importance in understanding the increased risk of postmenopausal breast and endometrial cancer in obese women. Peripheral conversion of androgenic precursors to estradiol by aromatase in adipose tissue is increased in obesity, leading to increased serum levels of estradiol, which, in turn, are insufficiently counterbalanced by levels of progesterone (47, 132). Furthermore, increased serum levels of insulin, as a result of adipose tissue dysfunction, can result in both increased ovarian androgen synthesis and reduced hepatic synthesis of sex-hormone-binding globulin (SHBG) (ref. 47). Recent findings of increased plasma concentrations of bioavailable estradiol and testosterone and decreased plasma concentration of SHBG in obese postmenopausal women are compatible with these mechanisms (132).

The role of endogenous sex steroids in the development and progression of breast and endometrial cancer is well established. Prospective studies show that levels of endogenous sex steroids are strongly associated with postmenopausal breast and endometrial cancer risk (133-136). The proliferative effect of estrogen on epithelial tissue of both breast and endometrium is believed to be the underlying mechanism (134, 137).

Several other obesity-associated risk factors could also contribute to the increased risk of some specific cancers.

Gastric acid reflux is more common among obese subjects (138). Since gastric acid reflux is a known risk factor for the development of esophageal adenocarcinoma, it is tempting to speculate that this is a mechanism contributing to the higher risk of this cancer in obesity. Interestingly, obesity is a risk factor for esophageal adenocarcinoma independently of acid reflux, which suggests that other factors associated with obesity are involved as well (139).

HIF-1α is considered an important factor in the development, growth, and metastasis of a large variety of cancer types (140-142). Of interest, recent studies show that HIF-1α is involved in the mechanisms underlying the overexpression of leptin in colorectal and breast tumors (86, 143). Hyperinsulinaemia might induce HIF-1α-mediated overexpression of leptin in breast cancer cells and so contribute to disease progression (143, 144). Furthermore, hypoxia in adipocytes increases the expression of MMPs and VEGF, suggesting that hypoxia in adipose tissue might be a modulator of the angiogenic process (145). These findings are consistent with clinical data that VEGF levels increase with increasing BMI (146). Because VEGF plays an important role in tumor angiogenesis (147), increased levels of this key endothelial mitogen may contribute to the poorer outcome of cancer in obese subjects.

Research interest is focusing on PPAR-γ, a ligand-inducible transcription factor, and its role in diabetes mellitus, arteriosclerosis, and cancer. PPAR-γ, which is mainly expressed in adipose tissue, is an important regulator of adipocyte differentiation and function, as well as cell proliferation and survival (148, 149). Down-regulation of PPAR-γ by TNF-α in obesity is believed to contribute to the dysfunction of adipose tissue (150). Because activation of PPAR-γ is associated with antitumor effects (151, 152), further attention should be paid to the role of PPAR-γ in carcinogenesis and the link between cancer and obesity, especially because it could become a therapeutic target.

Many tumors have increased levels of obesity-related factors, both adipokines and inflammatory components, in their microenvironment, and in some cases it is these tumors that are more aggressive (87, 94, 108, 117). Thus, the role of local obesity-related factors should be better determined in comparison to systemic levels. These local factors could be crucial in carcinogenesis and the role of peritumoural adipose tissue herein is yet to be established.

Although the above-mentioned and several other potential pathophysiological mechanisms have been proposed, their significance in the obesity-cancer link needs further exploration. It is possible that in obese individuals these mechanisms act synergistically to promote a multifactorial tumor-promoting environment. The significance of these mechanisms probably differs by tumor type, and so research should focus on the role of obesity in one particular cancer type at a time.

Adipose tissue dysfunction, as a consequence of obesity, is likely to play a role in carcinogenesis, by affecting insulin resistance and the production of several adipokines and inflammatory cytokines. Though the precise mechanisms may differ between different types of cancer, it is plausible that these mechanisms synergistically contribute to the increased cancer risk. While understanding the link between obesity and cancer might provide therapeutic targets, lifestyle improvement remains the most important component in preventing obesity-related morbidity and mortality. This needs to be addressed in intervention studies.

We searched for papers in PubMed and the Cochrane database, using search terms including “obesity,” “overweight,” “cancer,” “adipose tissue dysfunction,” “insulin resistance,” and “inflammation.” Bibliographies of included papers were scanned for other relevant papers. References were selected on the basis of relevance, importance, and novelty. Papers published in peer-reviewed journals as well as papers published in the past 3 years were preferentially treated.

No potential conflicts of interest were disclosed.

We gratefully acknowledge the contribution of J. Sykes (native speaker of English).

1
Ogden
CL
,
Carroll
MD
,
Curtin
LR
, et al
. 
Prevalence of overweight and obesity in the United States, 1999–2004
.
JAMA
2006
;
295
:
1549
55
.
2
Ogden
CL
,
Yanovski
SZ
,
Carroll
MD
,
Flegal
KM
. 
The epidemiology of obesity
.
Gastroenterology
2007
;
132
:
2087
102
.
3
World Health Organisation
.
Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity
.
Geneva
; 
2000
.
4
Calle
EE
,
Thun
MJ
,
Petrelli
JM
,
Rodriguez
C
,
Heath
CW
 Jr
. 
Body-mass index and mortality in a prospective cohort of U.S. adults
.
N Engl J Med
1999
;
341
:
1097
105
.
5
Hubert
HB
,
Feinleib
M
,
McNamara
PM
,
Castelli
WP
. 
Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study
.
Circulation
1983
;
67
:
968
77
.
6
Mokdad
AH
,
Ford
ES
,
Bowman
BA
, et al
. 
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
.
JAMA
2003
;
289
:
76
9
.
7
Flegal
KM
,
Graubard
BI
,
Williamson
DF
,
Gail
MH
. 
Cause-specific excess deaths associated with underweight, overweight, and obesity
.
JAMA
2007
;
298
:
2028
37
.
8
IARC Handbooks of Cancer Prevention
.
Weight Control and Physical Activity
.
Lyon (France)
:
International Agency for Research on Cancer Press
; 
2002
.
9
World Cancer Research Fund/American Institute for Cancer Research
.
Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective
.
Washington, DC
:
AICR
; 
2007
.
10
Reeves
GK
,
Pirie
K
,
Beral
V
, et al
. 
Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study
.
BMJ
2007
;
335
:
1134
.
11
Renehan
AG
,
Tyson
M
,
Egger
M
,
Heller
RF
,
Zwahlen
M
. 
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
.
Lancet
2008
;
371
:
569
78
.
12
Calle
EE
,
Rodriguez
C
,
Walker-Thurmond
K
,
Thun
MJ
. 
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults
.
N Engl J Med
2003
;
348
:
1625
38
.
13
Larsson
SC
,
Wolk
A
. 
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies
.
Am J Clin Nutr
2007
;
86
:
556
65
.
14
Moghaddam
AA
,
Woodward
M
,
Huxley
R
. 
Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events
.
Cancer Epidemiol Biomarkers Prev
2007
;
16
:
2533
47
.
15
Larsson
SC
,
Orsini
N
,
Wolk
A
. 
Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies
.
Int J Cancer
2007
;
120
:
1993
8
.
16
Hsing
AW
,
Sakoda
LC
,
Chua
S
 Jr
. 
Obesity, metabolic syndrome, and prostate cancer
.
Am J Clin Nutr
2007
;
86
:
s843
57
.
17
Bjorge
T
,
Engeland
A
,
Tverdal
A
,
Smith
GD
. 
Body mass index in adolescence in relation to cause-specific mortality: A follow-up of 230,000 Norwegian adolescents
.
Am J Epidemiol
2008
;
168
:
30
7
.
18
Xu
H
,
Barnes
GT
,
Yang
Q
, et al
. 
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
.
J Clin Invest
2003
;
112
:
1821
30
.
19
Skurk
T
,
Alberti-Huber
C
,
Herder
C
,
Hauner
H
. 
Relationship between adipocyte size and adipokine expression and secretion
.
J Clin Endocrinol Metab
2007
;
92
:
1023
33
.
20
Coppack
SW
,
Evans
RD
,
Fisher
RM
, et al
. 
Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal
.
Metabolism
1992
;
41
:
264
72
.
21
Hotamisligil
GS
,
Arner
P
,
Caro
JF
,
Atkinson
RL
,
Spiegelman
BM
. 
Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance
.
J Clin Invest
1995
;
95
:
2409
15
.
22
Wannamethee
SG
,
Lowe
GD
,
Rumley
A
, et al
. 
Adipokines and risk of type 2 diabetes in older men
.
Diabetes Care
2007
;
30
:
1200
5
.
23
Chu
NF
,
Spiegelman
D
,
Hotamisligil
GS
, et al
. 
Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men
.
Atherosclerosis
2001
;
157
:
495
503
.
24
Hajer
GR
,
van Haeften
TW
,
Visseren
FL
. 
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
.
Eur Heart J
2008
;
29
:
2959
71
.
25
Shulman
GI
. 
Cellular mechanisms of insulin resistance
.
J Clin Invest
2000
;
106
:
171
6
.
26
Wassink
AM
,
Olijhoek
JK
,
Visseren
FL
. 
The metabolic syndrome: metabolic changes with vascular consequences
.
Eur J Clin Invest
2007
;
37
:
8
17
.
27
Yamauchi
T
,
Kamon
J
,
Minokoshi
Y
, et al
. 
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
.
Nat Med
2002
;
8
:
1288
95
.
28
Arita
Y
,
Kihara
S
,
Ouchi
N
, et al
. 
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity
.
Biochem Biophys Res Commun
1999
;
257
:
79
83
.
29
Ramos
EJ
,
Xu
Y
,
Romanova
I
, et al
. 
Is obesity an inflammatory disease?
Surgery
2003
;
134
:
329
35
.
30
Bullo
M
,
Garcia-Lorda
P
,
Megias
I
,
Salas-Salvado
J
. 
Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression
.
Obes Res
2003
;
11
:
525
31
.
31
Weisberg
SP
,
McCann
D
,
Desai
M
, et al
. 
Obesity is associated with macrophage accumulation in adipose tissue
.
J Clin Invest
2003
;
112
:
1796
808
.
32
Neels
JG
,
Olefsky
JM
. 
Inflamed fat: what starts the fire?
J Clin Invest
2006
;
116
:
33
5
.
33
Wang
B
,
Wood
IS
,
Trayhurn
P
. 
Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes
.
Pflugers Arch
2007
;
455
:
479
92
.
34
Chen
B
,
Lam
KS
,
Wang
Y
, et al
. 
Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes
.
Biochem Biophys Res Commun
2006
;
341
:
549
56
.
35
Cancello
R
,
Henegar
C
,
Viguerie
N
, et al
. 
Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss
.
Diabetes
2005
;
54
:
2277
86
.
36
Bouloumie
A
,
Marumo
T
,
Lafontan
M
,
Busse
R
. 
Leptin induces oxidative stress in human endothelial cells
.
FASEB J
1999
;
13
:
1231
8
.
37
Jensen
MD
. 
Role of body fat distribution and the metabolic complications of obesity
.
J Clin Endocrinol Metab
2008
;
93
:
S57
63
.
38
Fontana
L
,
Eagon
JC
,
Trujillo
ME
,
Scherer
PE
,
Klein
S
. 
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans
.
Diabetes
2007
;
56
:
1010
3
.
39
Harman-Boehm
I
,
Bluher
M
,
Redel
H
, et al
. 
Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity
.
J Clin Endocrinol Metab
2007
;
92
:
2240
7
.
40
Cartier
A
,
Lemieux
I
,
Almeras
N
, et al
. 
Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-α in men
.
J Clin Endocrinol Metab
2008
;
93
:
1931
8
.
41
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
. 
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
.
JAMA
2001
;
285
:
2486
97
.
42
Cowey
S
,
Hardy
RW
. 
The metabolic syndrome: A high-risk state for cancer?
Am J Pathol
2006
;
169
:
1505
22
.
43
Strain
G
,
Zumoff
B
,
Rosner
W
,
Pi-Sunyer
X
. 
The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss
.
J Clin Endocrinol Metab
1994
;
79
:
1173
6
.
44
Leung
KC
,
Doyle
N
,
Ballesteros
M
,
Waters
MJ
,
Ho
KK
. 
Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation
.
J Clin Endocrinol Metab
2000
;
85
:
4712
20
.
45
Allen
NE
,
Appleby
PN
,
Kaaks
R
, et al
. 
Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women
.
Cancer Causes Control
2003
;
14
:
65
74
.
46
Pao
CI
,
Farmer
PK
,
Begovic
S
, et al
. 
Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by hormones and provision of amino acids in rat hepatocytes
.
Mol Endocrinol
1993
;
7
:
1561
8
.
47
Calle
EE
,
Kaaks
R
. 
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
.
Nat Rev Cancer
2004
;
4
:
579
91
.
48
Ricart
W
,
Fernandez-Real
JM
. 
No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance
.
Obes Res
2001
;
9
:
631
6
.
49
Pollak
MN
,
Schernhammer
ES
,
Hankinson
SE
. 
Insulin-like growth factors and neoplasia
.
Nat Rev Cancer
2004
;
4
:
505
18
.
50
Nickerson
T
,
Chang
F
,
Lorimer
D
, et al
. 
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR)
.
Cancer Res
2001
;
61
:
6276
80
.
51
Hellawell
GO
,
Turner
GD
,
Davies
DR
, et al
. 
Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease
.
Cancer Res
2002
;
62
:
2942
50
.
52
Bauer
TW
,
Liu
W
,
Fan
F
, et al
. 
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice
.
Cancer Res
2005
;
65
:
7775
81
.
53
Myers
MG
 Jr.
,
Backer
JM
,
Sun
XJ
, et al
. 
IRS-1 activates phosphatidylinositol 3′-kinase by associating with src homology 2 domains of p85
.
Proc Natl Acad Sci U S A
1992
;
89
:
10350
4
.
54
Carel
K
,
Kummer
JL
,
Schubert
C
, et al
. 
Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3–1 adipocytes
.
J Biol Chem
1996
;
271
:
30625
30
.
55
Gunter
MJ
,
Hoover
DR
,
Yu
H
, et al
. 
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
.
J Natl Cancer Inst
2009
;
101
:
48
60
.
56
Gunter
MJ
,
Hoover
DR
,
Yu
H
, et al
. 
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer
.
Cancer Epidemiol Biomarkers Prev
2008
;
17
:
921
9
.
57
Schoen
RE
,
Tangen
CM
,
Kuller
LH
, et al
. 
Increased blood glucose and insulin, body size, and incident colorectal cancer
.
J Natl Cancer Inst
1999
;
91
:
1147
54
.
58
Larsson
SC
,
Mantzoros
CS
,
Wolk
A
. 
Diabetes mellitus and risk of breast cancer: a meta-analysis
.
Int J Cancer
2007
;
121
:
856
62
.
59
Larsson
SC
,
Orsini
N
,
Brismar
K
,
Wolk
A
. 
Diabetes mellitus and risk of bladder cancer: a meta-analysis
.
Diabetologia
2006
;
49
:
2819
23
.
60
Larsson
SC
,
Orsini
N
,
Wolk
A
. 
Diabetes mellitus and risk of colorectal cancer: a meta-analysis
.
J Natl Cancer Inst
2005
;
97
:
1679
87
.
61
Huxley
R
,
Ansary-Moghaddam
A
,
Berrington de González
A
,
Barzi
F
,
Woodward
M
. 
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
.
Br J Cancer
2005
;
92
:
2076
83
.
62
Ouchi
N
,
Kihara
S
,
Funahashi
T
, et al
. 
Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue
.
Circulation
2003
;
107
:
671
4
.
63
Yamauchi
T
,
Kamon
J
,
Waki
H
, et al
. 
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
.
Nat Med
2001
;
7
:
941
6
.
64
Mantzoros
C
,
Petridou
E
,
Dessypris
N
, et al
. 
Adiponectin and breast cancer risk
.
J Clin Endocrinol Metab
2004
;
89
:
1102
7
.
65
Soliman
PT
,
Wu
D
,
Tortolero-Luna
G
, et al
. 
Association between adiponectin, insulin resistance, and endometrial cancer
.
Cancer
2006
;
106
:
2376
81
.
66
Goktas
S
,
Yilmaz
MI
,
Caglar
K
, et al
. 
Prostate cancer and adiponectin
.
Urology
2005
;
65
:
1168
72
.
67
Spyridopoulos
TN
,
Petridou
ET
,
Skalkidou
A
, et al
. 
Low adiponectin levels are associated with renal cell carcinoma: a case-control study
.
Int J Cancer
2007
;
120
:
1573
8
.
68
Wei
EK
,
Giovannucci
E
,
Fuchs
CS
,
Willett
WC
,
Mantzoros
CS
. 
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study
.
J Natl Cancer Inst
2005
;
97
:
1688
94
.
69
Igata
M
,
Motoshima
H
,
Tsuruzoe
K
, et al
. 
Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression
.
Circ Res
2005
;
97
:
837
44
.
70
Inoki
K
,
Zhu
T
,
Guan
KL
. 
TSC2 mediates cellular energy response to control cell growth and survival
.
Cell
2003
;
115
:
577
90
.
71
Ouedraogo
R
,
Wu
X
,
Xu
SQ
, et al
. 
Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway
.
Diabetes
2006
;
55
:
1840
6
.
72
Govindarajan
B
,
Klafter
R
,
Miller
MS
, et al
. 
Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase
.
Mol Med
2002
;
8
:
1
8
.
73
Grossmann
ME
,
Nkhata
KJ
,
Mizuno
NK
,
Ray
A
,
Cleary
MP
. 
Effects of adiponectin on breast cancer cell growth and signaling
.
Br J Cancer
2008
;
98
:
370
9
.
74
Yokota
T
,
Oritani
K
,
Takahashi
I
, et al
. 
Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages
.
Blood
2000
;
96
:
1723
32
.
75
Brakenhielm
E
,
Veitonmaki
N
,
Cao
R
, et al
. 
Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis
.
Proc Natl Acad Sci U S A
2004
;
101
:
2476
81
.
76
Hursting
SD
,
Nunez
NP
,
Varticovski
L
,
Vinson
C
. 
The obesity-cancer link: lessons learned from a fatless mouse
.
Cancer Res
2007
;
67
:
2391
3
.
77
Nunez
NP
,
Oh
WJ
,
Rozenberg
J
, et al
. 
Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation
.
Cancer Res
2006
;
66
:
5469
76
.
78
Munzberg
H
,
Myers
MG
 Jr.
Molecular and anatomical determinants of central leptin resistance
.
Nat Neurosci
2005
;
8
:
566
70
.
79
Stattin
P
,
Soderberg
S
,
Biessy
C
, et al
. 
Plasma leptin and breast cancer risk: a prospective study in northern Sweden
.
Breast Cancer Res Treat
2004
;
86
:
191
6
.
80
Chen
DC
,
Chung
YF
,
Yeh
YT
, et al
. 
Serum adiponectin and leptin levels in Taiwanese breast cancer patients
.
Cancer Lett
2006
;
237
:
109
14
.
81
Stattin
P
,
Lukanova
A
,
Biessy
C
, et al
. 
Obesity and colon cancer: does leptin provide a link?
Int J Cancer
2004
;
109
:
149
52
.
82
Stattin
P
,
Palmqvist
R
,
Soderberg
S
, et al
. 
Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden
.
Oncol Rep
2003
;
10
:
2015
21
.
83
Tamakoshi
K
,
Toyoshima
H
,
Wakai
K
, et al
. 
Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan
.
Oncology
2005
;
68
:
454
61
.
84
Petridou
E
,
Belechri
M
,
Dessypris
N
, et al
. 
Leptin and body mass index in relation to endometrial cancer risk
.
Ann Nutr Metab
2002
;
46
:
147
51
.
85
Cymbaluk
A
,
Chudecka-Glaz
A
,
Rzepka-Gorska
I
. 
Leptin levels in serum depending on Body Mass Index in patients with endometrial hyperplasia and cancer
.
Eur J Obstet Gynecol Reprod Biol
2008
;
136
:
74
7
.
86
Koda
M
,
Sulkowska
M
,
Kanczuga-Koda
L
, et al
. 
Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 α in human colorectal cancer
.
Ann Oncol
2007
;
18
:
vi116
9
.
87
Revillion
F
,
Charlier
M
,
Lhotellier
V
, et al
. 
Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers
.
Clin Cancer Res
2006
;
12
:
2088
94
.
88
Koda
M
,
Sulkowska
M
,
Wincewicz
A
, et al
. 
Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 α in human endometrial cancer
.
Ann N Y Acad Sci
2007
;
1095
:
90
8
.
89
Somasundar
P
,
Yu
AK
,
Vona-Davis
L
,
McFadden
DW
. 
Differential effects of leptin on cancer in vitro
.
J Surg Res
2003
;
113
:
50
5
.
90
Hoda
MR
,
Keely
SJ
,
Bertelsen
LS
, et al
. 
Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells
.
Br J Surg
2007
;
94
:
346
54
.
91
Hoda
MR
,
Popken
G
. 
Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells
.
BJU Int
2008
;
102
:
383
8
.
92
Bastelica
D
,
Morange
P
,
Berthet
B
, et al
. 
Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits
.
Arterioscler Thromb Vasc Biol
2002
;
22
:
173
8
.
93
Liang
X
,
Kanjanabuch
T
,
Mao
SL
, et al
. 
Plasminogen activator inhibitor-1 modulates adipocyte differentiation
.
Am J Physiol Endocrinol Metab
2006
;
290
:
E103
13
.
94
Dass
K
,
Ahmad
A
,
Azmi
AS
,
Sarkar
SH
,
Sarkar
FH
. 
Evolving role of uPA/uPAR system in human cancers
.
Cancer Treat Rev
2008
;
34
:
122
36
.
95
Andreasen
PA
,
Egelund
R
,
Petersen
HH
. 
The plasminogen activation system in tumor growth, invasion, and metastasis
.
Cell Mol Life Sci
2000
;
57
:
25
40
.
96
Rakic
JM
,
Maillard
C
,
Jost
M
, et al
. 
Role of plasminogen activator-plasmin system in tumor angiogenesis
.
Cell Mol Life Sci
2003
;
60
:
463
73
.
97
Look
MP
,
van Putten
WL
,
Duffy
MJ
, et al
. 
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
.
J Natl Cancer Inst
2002
;
94
:
116
28
.
98
Steiner
E
,
Pollow
K
,
Hasenclever
D
, et al
. 
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer
.
Gynecol Oncol
2008
;
108
:
569
76
.
99
Sakakibara
T
,
Hibi
K
,
Koike
M
, et al
. 
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer
.
Br J Cancer
2005
;
93
:
799
803
.
100
Ulisse
S
,
Baldini
E
,
Toller
M
, et al
. 
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas
.
Eur J Cancer
2006
;
42
:
2631
8
.
101
Ohba
K
,
Miyata
Y
,
Kanda
S
, et al
. 
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis
.
J Urol
2005
;
174
:
461
5
.
102
Gupta
A
,
Lotan
Y
,
Ashfaq
R
, et al
. 
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients
.
Eur Urol
2009
;
55
:
1124
33
.
103
Bajou
K
,
Maillard
C
,
Jost
M
, et al
. 
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth
.
Oncogene
2004
;
23
:
6986
90
.
104
Mutoh
M
,
Niho
N
,
Komiya
M
, et al
. 
Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice
.
Carcinogenesis
2008
;
29
:
824
9
.
105
Beaulieu
LM
,
Whitley
BR
,
Wiesner
TF
, et al
. 
Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle
.
BioEssays
2007
;
29
:
1029
38
.
106
Leik
CE
,
Su
EJ
,
Nambi
P
,
Crandall
DL
,
Lawrence
DA
. 
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis
.
J Thromb Haemost
2006
;
4
:
2710
5
.
107
Coussens
LM
,
Werb
Z
. 
Inflammation and cancer
.
Nature
2002
;
420
:
860
7
.
108
Aggarwal
BB
,
Shishodia
S
,
Sandur
SK
,
Pandey
MK
,
Sethi
G
. 
Inflammation and cancer: how hot is the link?
Biochem Pharmacol
2006
;
72
:
1605
21
.
109
Eaden
JA
,
Abrams
KR
,
Mayberry
JF
. 
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
.
Gut
2001
;
48
:
526
35
.
110
Jess
T
,
Gamborg
M
,
Matzen
P
,
Munkholm
P
,
Sorensen
TI
. 
Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies
.
Am J Gastroenterol
2005
;
100
:
2724
9
.
111
Spechler
SJ
,
Goyal
RK
. 
The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett
.
Gastroenterology
1996
;
110
:
614
21
.
112
Visser
M
,
Bouter
LM
,
McQuillan
GM
,
Wener
MH
,
Harris
TB
. 
Elevated C-reactive protein levels in overweight and obese adults
.
JAMA
1999
;
282
:
2131
5
.
113
Fogarty
AW
,
Glancy
C
,
Jones
S
, et al
. 
A prospective study of weight change and systemic inflammation over 9 y
.
Am J Clin Nutr
2008
;
87
:
30
5
.
114
Heikkila
K
,
Harris
R
,
Lowe
G
, et al
. 
Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis
.
Cancer Causes Control
2008
;
20
:
15
26
.
115
Locksley
RM
,
Killeen
N
,
Lenardo
MJ
. 
The TNF and TNF receptor superfamilies: integrating mammalian biology
.
Cell
2001
;
104
:
487
501
.
116
Carswell
EA
,
Old
LJ
,
Kassel
RL
, et al
. 
An endotoxin-induced serum factor that causes necrosis of tumors
.
Proc Natl Acad Sci U S A
1975
;
72
:
3666
70
.
117
Kulbe
H
,
Thompson
R
,
Wilson
JL
, et al
. 
The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells
.
Cancer Res
2007
;
67
:
585
92
.
118
Suganuma
M
,
Okabe
S
,
Marino
MW
, et al
. 
Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice
.
Cancer Res
1999
;
59
:
4516
8
.
119
Davies
FE
,
Rollinson
SJ
,
Rawstron
AC
, et al
. 
High-producer haplotypes of tumor necrosis factor α and lymphotoxin α are associated with an increased risk of myeloma and have an improved progression-free survival after treatment
.
J Clin Oncol
2000
;
18
:
2843
51
.
120
Chen
G
,
Goeddel
DV
. 
TNF-R1 signaling: a beautiful pathway
.
Science
2002
;
296
:
1634
5
.
121
Varfolomeev
EE
,
Ashkenazi
A
. 
Tumor necrosis factor: an apoptosis JuNKie?
Cell
2004
;
116
:
491
7
.
122
Balkwill
F
. 
TNF-α in promotion and progression of cancer
.
Cancer Metastasis Rev
2006
;
25
:
409
16
.
123
Il'yasova
D
,
Colbert
LH
,
Harris
TB
, et al
. 
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort
.
Cancer Epidemiol Biomarkers Prev
2005
;
14
:
2413
8
.
124
Kim
S
,
Keku
TO
,
Martin
C
, et al
. 
Circulating levels of inflammatory cytokines and risk of colorectal adenomas
.
Cancer Res
2008
;
68
:
323
8
.
125
Naugler
WE
,
Karin
M
. 
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
.
Trends Mol Med
2008
;
14
:
109
19
.
126
Cozen
W
,
Gebregziabher
M
,
Conti
DV
, et al
. 
Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma
.
Cancer Epidemiol Biomarkers Prev
2006
;
15
:
2285
91
.
127
Heinrich
PC
,
Behrmann
I
,
Haan
S
, et al
. 
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
.
Biochem J
2003
;
374
:
1
20
.
128
Egeblad
M
,
Werb
Z
. 
New functions for the matrix metalloproteinases in cancer progression
.
Nat Rev Cancer
2002
;
2
:
161
74
.
129
Chavey
C
,
Mari
B
,
Monthouel
MN
, et al
. 
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation
.
J Biol Chem
2003
;
278
:
11888
96
.
130
Motrescu
ER
,
Rio
MC
. 
Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle
.
Biol Chem
2008
;
389
:
1037
41
.
131
Katiyar
SK
,
Meeran
SM
. 
Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-κB signaling
.
Free Radic Biol Med
2007
;
42
:
299
310
.
132
Baglietto
L
,
English
DR
,
Hopper
JL
, et al
. 
Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition
.
Breast Cancer Res Treat
2009
;
115
:
171
9
.
133
Allen
NE
,
Key
TJ
,
Dossus
L
, et al
. 
Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC)
.
Endocr Relat Cancer
2008
;
15
:
485
97
.
134
Kaaks
R
,
Lukanova
A
,
Kurzer
MS
. 
Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review
.
Cancer Epidemiol Biomarkers Prev
2002
;
11
:
1531
43
.
135
Key
T
,
Appleby
P
,
Barnes
I
,
Reeves
G
. 
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies
.
J Natl Cancer Inst
2002
;
94
:
606
16
.
136
Tamimi
RM
,
Byrne
C
,
Colditz
GA
,
Hankinson
SE
. 
Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women
.
J Natl Cancer Inst
2007
;
99
:
1178
87
.
137
Travis
RC
,
Key
TJ
. 
Oestrogen exposure and breast cancer risk
.
Breast Cancer Res
2003
;
5
:
239
47
.
138
Nilsson
M
,
Johnsen
R
,
Ye
W
,
Hveem
K
,
Lagergren
J
. 
Obesity and estrogen as risk factors for gastroesophageal reflux symptoms
.
JAMA
2003
;
290
:
66
72
.
139
Lagergren
J
. 
Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma
.
Lancet Oncol
2006
;
7
:
347
9
.
140
Jiang
BH
,
Agani
F
,
Passaniti
A
,
Semenza
GL
. 
V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression
.
Cancer Res
1997
;
57
:
5328
35
.
141
Gort
EH
,
Groot
AJ
,
van der Wall
E
,
van Diest
PJ
,
Vooijs
MA
. 
Hypoxic regulation of metastasis via hypoxia-inducible factors
.
Curr Mol Med
2008
;
8
:
60
7
.
142
Zhong
H
,
De Marzo
AM
,
Laughner
E
, et al
. 
Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
.
Cancer Res
1999
;
59
:
5830
5
.
143
Cascio
S
,
Bartella
V
,
Auriemma
A
, et al
. 
Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α
.
Oncogene
2008
;
27
:
540
7
.
144
Bartella
V
,
Cascio
S
,
Fiorio
E
, et al
. 
Insulin-dependent leptin expression in breast cancer cells
.
Cancer Res
2008
;
68
:
4919
27
.
145
Lolmede
K
,
Durand de
SFV
,
Galitzky
J
,
Lafontan
M
,
Bouloumie
A
. 
Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3–442A adipocytes
.
Int J Obes Relat Metab Disord
2003
;
27
:
1187
95
.
146
Silha
JV
,
Krsek
M
,
Sucharda
P
,
Murphy
LJ
. 
Angiogenic factors are elevated in overweight and obese individuals
.
Int J Obes (Lond)
2005
;
29
:
1308
14
.
147
Kerbel
RS
. 
Tumor angiogenesis
.
N Engl J Med
2008
;
358
:
2039
49
.
148
Michalik
L
,
Desvergne
B
,
Wahli
W
. 
Peroxisome-proliferator-activated receptors and cancers: complex stories
.
Nat Rev Cancer
2004
;
4
:
61
70
.
149
Tamori
Y
,
Masugi
J
,
Nishino
N
,
Kasuga
M
. 
Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3–1 adipocytes
.
Diabetes
2002
;
51
:
2045
55
.
150
Guilherme
A
,
Virbasius
JV
,
Puri
V
,
Czech
MP
. 
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes
.
Nat Rev Mol Cell Biol
2008
;
9
:
367
77
.
151
Sarraf
P
,
Mueller
E
,
Jones
D
, et al
. 
Differentiation and reversal of malignant changes in colon cancer through PPARγ
.
Nat Med
1998
;
4
:
1046
52
.
152
Mueller
E
,
Smith
M
,
Sarraf
P
, et al
. 
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer
.
Proc Natl Acad Sci U S A
2000
;
97
:
10990
5
.